Homepage > Company > Media > Pharma News > 2020 > East China city to build "Chinese pharma valley"

East China city to build "Chinese pharma valley"

The city of Suzhou in east China's Jiangsu Province aims to build a "Chinese pharma valley" by 2030, according to a biomedical development conference held in the city on Saturday.

The city plans to attract more than 10,000 bio-pharmaceutical enterprises with an industrial scale of over 1 trillion yuan (about 141.21 billion U.S. dollars) by 2030.

Encouraging the enterprises to set up regional headquarters in Suzhou, the city will offer a maximum subsidy of 60 million yuan to those companies that meet conditions.

The annual turnover of Suzhou's bio-pharmaceutical industry has exceeded 170 billion yuan, and the city has attracted more than 3,000 bio-pharmaceutical enterprises.

The number of newly approved drugs in the city accounted for 3.6 percent of the country's total in 2019.

2020-04-25

http://www.xinhuanet.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)